Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea Source: Eur Respir J, 51 (3) 1702467; 10.1183/13993003.02467-2017 Year: 2018
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China Source: Eur Respir J , 49 (3) 1601558; DOI: 10.1183/13993003.01558-2016 Year: 2017
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013
Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysisSource: Eur Respir J, 50 (4) 1701044; 10.1183/13993003.01044-2017 Year: 2017
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019
Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Surgical treatment for MDR TB patients – preliminary results from a Romanian MDR TB centre Source: Eur Respir J 2006; 28: Suppl. 50, 276s Year: 2006
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk Source: Eur Respir J 2012; 39: 1425-1431 Year: 2012